2,6-Hexadecadiynoic acid and 2,6-nonadecadiynoic acid: Novel synthesized acetylenic fatty acids as potent antifungal agents
Lipids, ISSN: 0024-4201, Vol: 41, Issue: 5, Page: 507-511
2006
- 22Citations
- 245Usage
- 10Captures
- 1Mentions
Metric Options: CountsSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Citations22
- Citation Indexes22
- 22
- CrossRef21
- Usage245
- Downloads239
- Abstract Views6
- Captures10
- Readers10
- 10
- Mentions1
- References1
- Wikipedia1
Article Description
The hitherto unknown 2,6-hexadecadiynoic acid, 2,6-nonadecadiynoic acid, and 2,9-hexadecadiynoic acid were synthesized in two steps and in 11-18% overall yields starting from either 1,5-hexadiyne or 1,8-nonadiyne. Among all the compounds 2,6-hexadecadiynoic acid displayed the best overall antifungal activity against both the fluconazole-resistant Candida albicans strains ATCC 14053 and ATCC 60193, with a minimum inhibitory concentration (MIC of 11 μM), and against Cryptococcus neoformans ATCC 66031 (MIC < 5.7 μM). 2,9-Hexadecadiynoic acid did not display any significant cytotoxicity against the fluconazole-resistant C. albicans strains, but it showed fungitoxicity against C. neoformans ATCC 66031 with a MIC value of < 5.8 μM. Other FA, such as 2-hexadecynoic acid, 5-hexadecynoic acid, 9-hexadecynoic acid, and 6-nonadecynoic acid were also synthesized and their antifungal activities compared with those of the novel acetylenic FA. 2-Hexadecynoic acid, a known antifungal FA, exhibited the best antifungal activity (MIC = 9.4 μM) against the fluconazole-resistant C. albicans ATCC 14053 strain, but it showed a MIC value of only 100 μM against C. albicans ATCC 60193. 2,6-Hexadecadiynoic acid and 2-hexadecynoic acid also displayed a MIC of 140-145 μM toward Mycobacterium tuberculosis HRv in Middlebrook 7H12 medium. In conclusion, 2,6-hexadecadiynoic acid exhibited the best fungitoxicity profile compared with other analogues. This diynoic FA has the potential to be further evaluated for use in topical antifungal formulations. Copyright © 2006 by AOCS Press.
Bibliographic Details
https://digitalcommons.uri.edu/bps_facpubs/174; https://digitalcommons.chapman.edu/pharmacy_articles/71
http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=33746985016&origin=inward; http://dx.doi.org/10.1007/s11745-006-5124-4; http://www.ncbi.nlm.nih.gov/pubmed/16933795; https://aocs.onlinelibrary.wiley.com/doi/10.1007/s11745-006-5124-4; https://digitalcommons.uri.edu/bps_facpubs/174; https://digitalcommons.uri.edu/cgi/viewcontent.cgi?article=1185&context=bps_facpubs; https://digitalcommons.chapman.edu/pharmacy_articles/71; https://digitalcommons.chapman.edu/cgi/viewcontent.cgi?article=1075&context=pharmacy_articles; https://dx.doi.org/10.1007/s11745-006-5124-4; https://aocs.onlinelibrary.wiley.com/doi/abs/10.1007/s11745-006-5124-4; http://www.springerlink.com/index/10.1007/s11745-006-5124-4; http://www.springerlink.com/index/pdf/10.1007/s11745-006-5124-4; http://link.springer.com/10.1007/s11745-006-5124-4; https://link.springer.com/article/10.1007/s11745-006-5124-4; https://link.springer.com/content/pdf/10.1007%2Fs11745-006-5124-4.pdf; https://link.springer.com/article/10.1007%2Fs11745-006-5124-4
Wiley
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know